Develops drugs for autoimmune and inflammatory diseases.
Mar 2026Revenue $232M/yrExpenses $12.6M/yr
Reached break-even Dec 2024
Figures by year
When did Anaptysbio become profitable?
Its revenue passed its expenses in Dec 2024. In the 12 months to Mar 2026, revenue was $232M and expenses $12.6M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $235M | $7.70M | $227M |
| Dec 2024 | $91.3M | $25.1M | $66.2M |
| Dec 2023 | $17.2M | $182M | −$164M |
| Dec 2022 | $10.3M | $125M | −$115M |
| Dec 2021 | $63.2M | $120M | −$56.8M |
| Dec 2020 | $75.0M | $98.9M | −$23.9M |
| Dec 2019 | $8.00M | $115M | −$107M |
| Dec 2018 | $5.00M | $71.7M | −$66.7M |
| Dec 2017 | $10.0M | $38.8M | −$28.8M |
| Dec 2016 | $16.7M | $19.7M | −$3.02M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.